Ipsen S.A. (IPN.PA)
- Previous Close
112.30 - Open
112.60 - Bid --
- Ask --
- Day's Range
111.40 - 113.00 - 52 Week Range
99.70 - 130.70 - Volume
55,575 - Avg. Volume
77,016 - Market Cap (intraday)
9.346B - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
15.27 - EPS (TTM)
7.40 - Earnings Date Jul 24, 2024
- Forward Dividend & Yield 1.20 (1.07%)
- Ex-Dividend Date May 30, 2024
- 1y Target Est
124.40
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
www.ipsen.com5,325
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: IPN.PA
Performance Overview: IPN.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPN.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPN.PA
Valuation Measures
Market Cap
9.29B
Enterprise Value
9.07B
Trailing P/E
15.18
Forward P/E
13.24
PEG Ratio (5yr expected)
6.25
Price/Sales (ttm)
2.83
Price/Book (mrq)
2.43
Enterprise Value/Revenue
2.74
Enterprise Value/EBITDA
10.22
Financial Highlights
Profitability and Income Statement
Profit Margin
19.49%
Return on Assets (ttm)
9.02%
Return on Equity (ttm)
17.30%
Revenue (ttm)
3.31B
Net Income Avi to Common (ttm)
617.1M
Diluted EPS (ttm)
7.40
Balance Sheet and Cash Flow
Total Cash (mrq)
528.4M
Total Debt/Equity (mrq)
12.11%
Levered Free Cash Flow (ttm)
838.15M
Research Analysis: IPN.PA
Company Insights: IPN.PA
IPN.PA does not have Company Insights